



Connecticut Medical Assistance Program
Policy Transmittal 2025-36

Provider Bulletin 2025-79
December 2025

Andrea Barton Reeves, J.D., Commissioner

Effective Date: January 1, 2026
Contact: see below

TO: Pharmacy Providers, Physicians, Nurse Practitioners, Physician Assistants and Hospitals

**RE: 1. New J Code for Billing Spravato®
2. Spravato® Coverage Guidelines**

This provider bulletin (PB) supersedes guidance found in [PB 20-83](#) Spravato® Coverage Guidelines.

For dates of service, January 1, 2026 and forward, the Department of Social Services (DSS) will be updating the physician office and outpatient fee schedule with the new procedure code, J0013 for Esketamine nasal spray, marketed as Spravato® for HUSKY A, HUSKY B, HUSKY C, and HUSKY D members.

The U.S. Food and Drug Administration (FDA) approved Spravato® (Esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them (treatment-resistant depression) and acute suicidal ideation.

Because of the risk of serious adverse outcomes resulting from sedation and dissociation caused by Spravato® administration, and the potential for abuse and misuse of the drug, it is only available through a restricted distribution system, under a Risk Evaluation and Mitigation Strategy (REMS). Details and additional information regarding the Spravato® REMS can be found at <https://www.spravatorems.com/>.

The Spravato® Coverage Guideline document is available on the www.ctdssmap.com

[Web page under Pharmacy Information → Pharmacy Program Publications → Spravato® Coverage Guidelines.](#)

The guidelines can also be found on the Connecticut Behavioral Health Partnership (CT BHP) Web site at: www.ctbhp.com web page under For Providers → Provider Resources → Level of Care Guidelines.

Please note that Spravato® will be authorized for a period of no more than six (6) months and requires re-authorization after the initial prior authorization (PA) ends.

Pharmacy Prior Authorization Submission Process

PA requests for coverage of Spravato® must be submitted by the prescriber using the Spravato® PA form located on the www.ctdssmap.com

Web site. From the Home page, go to Pharmacy Information → Pharmacy Program Publications → Spravato® PA Form.

When the clinical criteria are not met, a letter of medical necessity must be faxed to CT BHP at 1-860-434-7681 with all relevant information relating to the medical necessity.

Outpatient Hospital and Physician Prior Authorization Submission Process

Outpatient providers buying and billing for Spravato® must utilize a separate PA process identified below. Outpatient hospital providers must fax a completed Spravato® PA Request Form along with the required

documentation to CT BHP at 1-860-434-7681.

The Spravato® PA Request Form for outpatient hospitals is available on CT BHP Web site at: www.ctbhp.com web page under For Providers → Provider Resources → Forms.

For questions regarding the PA process for outpatient hospitals, please contact CT BHP at 1-877-552-8247 or at CTBHP@BeaconHealthOptions.com.

Billing Guidance – If you Purchase, Administer and Bill for Spravato®

Outpatient Hospitals:

Two dose-specific procedure codes (G2082 and G2083) for the provision of the drug and the professional services associated with Spravato® therapy have been added to the CMAP Addendum B. The following table describes the G codes. Selection of the appropriate code is dose dependent.

| HCPCS Code | Description |
|------------|--|
| G2082 | Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified healthcare professional and provision of up to 56 mg of esketamine nasal self-administration, includes 2 hours post-administration observation. |
| G2083 | Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified healthcare professional and provision of greater than 56 mg of esketamine nasal self-administration, includes 2 hours post-administration observation. |

Since procedure codes G2082 and G2083 describe both the drug and the professional services, when the drug is administered in the outpatient hospital setting there cannot be a separate professional claim submitted. The

reimbursement rates for the G-codes on CMAP Addendum B is an all-inclusive rate. Outpatient hospitals should bill Spravato® in conjunction with Revenue Center Code (RCC) 919.

Physician Office (Updated):

Effective for dates of service January 1, 2026, when separately reported, Spravato® should be billed with the new procedure code J0013- Esketamine, nasal spray.

For dates of service December 31, 2025 and prior, when separately reported, Spravato® should be billed with S0013 – Esketamine, nasal spray, 1 mg.

Procedure code J3490 – unclassified drug should no longer be billed when Spravato® is listed on the claim separately.

Physicians administering and performing the required monitoring of Spravato® should bill one of the appropriate evaluation and management (E&M) codes:

| HCPCS Code | Description |
|---------------|--|
| 99202 - 99205 | Office or other outpatient visit for the evaluation and management of a new patient |
| 99212- 99215 | Office or other outpatient visit for the evaluation and management of an established patient |

Billing Guidance – For the Administration of Spravato® Only

When the drug is supplied by a Risk Evaluation and Mitigation Strategy (REMS)-certified pharmacy, it cannot be billed by the administering provider; however, the administration of the drug and required monitoring is covered under one of the appropriate E&M codes listed above.

Accessing the Fee Schedule:

The fee schedule can be accessed and downloaded by going to the Connecticut Medical Assistance (CMAP) Web site: www.ctdssmap.com. From this Web page, go to “Provider”, then to “Provider Fee Schedule

Download", then click on the appropriate fee schedule. To access the CSV file, press the control key while clicking the CSV link, then select "Open".

Accessing CMAP Addendum B:

CMAP's Addendum B can be accessed via the www.ctdssmap.com Web site by selecting the "Hospital Modernization" Web page. CMAP's Addendum B (Excel) is located under "Important Messages – Connecticut Hospital Modernization".

For questions about billing or if further assistance is needed to access the fee schedule on the Connecticut Medical Assistance Program Web site, please contact the Provider Assistance Center, Monday through Friday from 8:00 a.m. to 5:00 p.m. at 1-800-842-8440.

Posting Instructions: Policy transmittals can be downloaded from the Web site at www.ctdssmap.com.

Distribution: This policy transmittal is being distributed to providers of the CMAP by Gainwell Technologies.

Responsible Unit:

DSS, Division of Health Services, Medical Policy Section; Dana Robinson-Rush, Health Program Assistant, email at dana.robinson-rush@ct.gov.

DSS, Division of Health Services, Integrated Care Unit; Hector Massari, email at hector.massari@ct.gov.

Date Issued: December 2025